MelanomaNext®

MelanomaNext is a next generation sequencing panel that simultaneously analyzes 9 genes associated with increased risk for melanoma and other cancers.
Quick Reference
Test Code 8849
Turnaround Time (TAT) 14-21 days
Number of Genes 9

+RNAinsight®

Add +RNAinsight to your genetic test order today.

Learn more

Ordering Options

We offer family variant testing at no additional cost

for all blood relatives of patients who undergo full single gene sequencing, multigene panel testing or exome sequencing at Ambry Genetics and are found to have a pathogenic or likely pathogenic variant. No-cost testing of blood relatives must be completed within 90 days of the original report date. Whenever possible, more closely related relatives should be tested before more distant relatives.

Order Now

Why Is This Important?

  1. Option to modify frequency and initial age of cancer screening, as appropriate
  2. Consideration of risk-reducing measures, as appropriate 
  3. Identify at-risk family members 

When To Consider Testing

  • Multiple primary melanomas
  • Multiple close relatives* with melanoma, with or without pancreatic cancer
  • Melanoma and kidney cancer (or mesothelioma) in the same person, or close relatives*
  • A family history of a mutation in a gene that predisposes to melanoma

      * On the same side of the family

Mutation Detection Rate

MelanomaNext can detect >99.9% of described mutations in the included genes listed above, when present (analytic sensitivity).

Test Description

MelanomaNext analyzes 9 genes (listed above). All genes are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. The BRCA2 Portuguese founder mutation, c.156_157insAlu (also known as 384insAlu) is detected by NGS and confirmed by MLPA. For MITF, only the status of the c.952G>A (p.E318K) alteration is analyzed and reported. Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Potentially homozygous variants, variants in regions complicated by pseudogene interference, and variant calls not satisfying depth of coverage and variant allele frequency quality thresholds are verified by Sanger sequencing. Gross deletion/duplication analysis is performed for the covered exons and untranslated regions of all sequenced genes (excluding MITF) using read-depth from NGS data with confirmatory multiplex ligation-dependent probe amplification (MLPA) and/or targeted chromosomal microarray. 

View Full Menu

Search Results

Start your search...